NTLA Q1 2021 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-50.1% YoY

Gross Profit

-$33M-509.4% margin

Operating Income

-$46M-720.3% margin

Net Income

-$46M-716.9% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

-2.3%

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$55M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$717M

Total Liabilities

$171M

Stockholders' Equity

$546M

Cash & Equivalents

$142M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$13M	-50.1%
Gross Profit	-$33M	-$22M	-51.1%
Operating Income	-$46M	-$33M	-40.5%
Net Income	-$46M	-$32M	-45.3%